NOVARTIS logo.jpg
Novartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye”
April 20, 2020 01:17 ET | Novartis International AG
Technology has potential to reimagine treatment for amblyopia (“lazy eye”), a leading cause of vision loss in children and young adults1Acquisition expands the Novartis refractive disorder pipeline in...
NOVARTIS logo.jpg
Novartis to acquire worldwide adult medical nutrition business of
December 16, 2003 01:28 ET | Novartis Pharma AG
Novartis to acquire worldwide adult medical nutrition business of Mead Johnson & Company, strengthening its number two global position   ...
NOVARTIS logo.jpg
Sandoz acquires antibiotics production facility
December 11, 2003 01:30 ET | Novartis Pharma AG
Sandoz acquires antibiotics production facility in Spain Acquisition strengthens in-house production and adds freeze-drying technology Vienna, 11 December 2003 - Sandoz, the generics business unit of...
NOVARTIS logo.jpg
Novartis ehrt Wissenschaftler
December 09, 2003 03:40 ET | Novartis Pharma AG
Novartis ehrt Wissenschaftler für herausragende Beiträge   Höchste interne wissenschaftliche Auszeichnung geht an Chemiker, der an der Entdeckung von Glivec® massgeblich beteiligt...
NOVARTIS logo.jpg
Post-tamoxifen Use Of Femara In Postmenopausal Women With Early Breast Cancer Reduced Risk Of Recurrence By Nearly Half (43%) and Significantly Improved Disease-Free Survival, According to Data Presented at Major Medical Meeting
December 08, 2003 03:00 ET | Novartis Pharma AG
Extended adjuvant data presented at San Antonio Breast Cancer Symposium supported by new data on quality of life with Femara vs. placebo, from same clinical trialEast Hanover, NJ, December 5, 2003 -...
NOVARTIS logo.jpg
New Data Show Higher Dosing of Gleevec Achieved Higher Response Rates in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML)
December 08, 2003 03:00 ET | Novartis Pharma AG
Early Findings Among Clinical Research Presented at American Society of Hematology (ASH) Meeting; At 12 months, 92% of evaluable CML patients taking 800 mg Gleevec achieved a CCR compared to 72%...